Potential of Aeginetia indica for Alzheimer's Disease Management: In Vitro, In Vivo, and Computational Insights Authors: Marjanur Rahman Bhuiyan, Md Sharif Reza, Sadikur Rahman Shuvo, Mustafa Abdullah Yilmaz, Syed Mumtahin Mannan Siam, Md Shadman Sakib, Oguz Cakir, Md Nazmul Islam Durjoy, Abbas Tarhan, Nuraniye Eruygur, A F M Shahid Ud Daula Published: 2026 ABSTRACT ABSTRACTThe 2023 Alzheimer's Disease International report warns that Alzheimer's disease (AD) is an escalating global challenge, with estimates suggesting more than 150 million cases worldwide by 2050 and about 13.8 million in the United States by 2060. AD is often linked with cholinergic dysfunction and increased acetylcholinesterase (AChE) activity, exacerbated by chronic neuroinflammation and oxidative stress. This study investigates the potential of Aeginetia indica whole plant methanolic extract (AiME) and its phytochemicals as natural AChE inhibitors (AChEIs) for AD management. AiME (IC50 = 176.586 ± 5.96 μg/mL) exhibited moderate, dose‐dependent antioxidant activity compared to standard ascorbic acid (IC50 = 38.866 ± 10.059 μg/mL) in the DPPH antioxidant assay. The other two antioxidant assays, reducing power activity (RPA) and ferric‐reducing antioxidant power (FRAP), also followed a similar trend (AiME: EC50 = 358.249 ± 16.605 μg/mL, EC50 = 39.467 ± 9.046 μg/mL), respectively, compared to standard ascorbic acid (Std: EC50 = 53.778 ± 0.624 μg/mL, Std: EC50 = 48.986 ± 0.512 μg/mL). AiME at all doses showed significant inhibition (p < 0.001) of paw edema in animals (in vivo) compared to the negative control group. Notably, AiME displayed better AChE inhibitory activity (IC50 = 1.636 ± 0.067 mg/mL) compared to standard rivastigmine (IC50 = 2.344 ± 0.151 mg/mL) in the acetylcholinesterase assay. LCMS/MS analysis identified 16 phenolic compounds, and GCMS analysis revealed 23 phytoconstituents in AiME. Molecular docking studies revealed acteoside, acacetin, and luteolin as promising leads, exhibiting favorable binding affinities and hydrogen bond interactions with the AChE active site. The structural stability and rigidity of our top two lead compounds, acteoside and acacetin, were evaluated using 100 ns molecular dynamics simulations, where they exhibited lower root mean square deviation values, with the acteoside‐AChE complex ranging from 0.1 to 0.35 nm and the acacetin‐AChE complex ranging from 0.1 to 0.4 nm, indicating notable stability. This study highlights the potential of A. indica and its phenolic constituents as natural alternatives for AD management, offering a multi‐pronged mechanistic pathway through AChE inhibition, anti‐inflammatory, and antioxidant properties.Keywords: carrageenan induced anti‐inflammatory assay, DPPH‐free radical scavenging assay, ferric‐reducing antioxidant power assay, LCMS/MS and GCMS analysis, molecular docking and dynamics simulation, reducing power activity assay Introduction Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders, characterized by a profound decline in cognitive functions (Yang et al. 2017). It has become a significant concern among older patients affecting around 5.5 million people in the US alone (Rehman et al. 2022). The Alzheimer's Disease International 2023 report (“2023 Alzheimer's Disease Facts and Figures” 2023) has projected that the total number of AD cases will increase from 50 million in 2018 to approximately 150 million by 2050, with about 13.8 million in the United States by 2060, and it is also expected to witness a doubling in the number of cases in Europe (Li et al. 2022; Scheltens et al. 2021). During the early stages of AD, patients experience mild symptoms such as memory loss, behavioral changes, and impaired communication skills. As the disease progresses, these symptoms lead to a severe decline in cognitive functions including movement disabilities, complete memory loss, and disorientation (Rehman et al. 2022). Two hallmark pathological features of Alzheimer's disease are neurofibrillary tangles (NFTs) and senile plaques (SPs) (Kumar et al. 2015; Scheltens et al. 2021; Yang et al. 2017). Senile plaques are amyloid plaques that contribute to cerebral amyloid angiopathy (CAA) through the deposition of Aβ proteins in the brain's parenchyma and cerebral blood vessels (Kumar et al. 2015). Aβ42 isoforms of amyloid‐β (Aβ) are particularly critical for the progression of AD, as they exhibit greater aggregation propensity and neurotoxicity compared to other isoforms, Aβ40 (Yang et al. 2017). On the other hand, NFTs arise from the hyperphosphorylation of tau protein within neurons, following the steps of neuroinflammation in Alzheimer's disease patients' brains (Jain et al. 2024). Consequently, the acetylcholinesterase enzyme (AChE) becomes upregulated, leading to the hydrolysis of acetylcholine (Ach), a vital neurotransmitter at the synaptic cleft. This process causes a deficiency of acetylcholine at nerve endings, impairing nerve impulses and contributing significantly to the progression of AD. Acetylcholinesterase inhibitors (AChEIs) are the first line therapeutic agents currently considered for patients with Alzheimer's disease. AChEIs restore diminished acetylcholine (Ach) levels at the synaptic cleft by blocking the upregulation of AChE, a direct consequence of hyperphosphorylation of tau proteins (NFTs), one hallmark of AD described above. Several AChEIs, such as rivastigmine, donepezil, and galantamine, have received approval for Alzheimer's disease treatment from regulatory bodies in more than 60 countries (Birks and Grimley Evans 2015). However, the efficacy of these drugs remains a subject of debate, with some studies claiming half of the populations treated with these drugs ended up with no efficient response (Kumar et al. 2015). Additionally, AChEIs are also reported with potential serious cholinergic adverse effects including hepatotoxicity, bone fractures, eczema rash, unusual weakness, gastrointestinal disturbances, and nocturia (Rehman et al. 2022). These harmful side effects limit their clinical use in patients and demand for developing natural sources‐based alternatives with a more favorable safety profile. Moreover, more recent research suggests persistent neuroinflammation and oxidative stress in the brain as another third core pathophysiological mechanism in AD, alongside the two established hallmarks of SPs and NFTs (Agostinho et al. 2010). Therefore, considering the limitations of current therapeutic options and the recently proposed link between neuroinflammation and oxidative stress in Alzheimer's disease, we aim to investigate the antioxidant, anti‐inflammatory, and acetylcholinesterase (AChE) inhibitory activities of the parasitic plant Aeginetia indica , which has a history of medicinal use in Asia (On‐Nom et al. 2024). The parasitic herb plant A. indica predominantly grows in various Asian countries (Liu et al. 2012). It is especially abundant in the Chittagong Hill Tracts of Bangladesh. This plant is well known by the two local names “Min Mukhi” and “Buishakful Gulu” inside Bangladesh. Aeginetia indica has a rich history for consuming in various ways across Asia. For instance, Thai people use it as a food colorant in their different desserts (Liu et al. 2012). In Nepal, the root juice from this herb is used to treat fever (Sapkota 2014). In Myanmar and New Guinea, the whole plant of A. indica was consumed orally for knee pain, throat discomfort, and urinary tract infections (Hong et al. 2015; Parnell 2001). Several other studies also reported the various uses of A. indica for different pharmacological activities against Hepatitis C and renal cancer cell growth (Lin et al. 2018), angiogenesis (Bhuiyan et al. 2025). Few other pharmacological activities from A. indica , such as analgesic, antipyretic, antidiabetic, and hepatoprotective activities, were also reported from our lab (Reza et al. 2021, 2020). The diverse traditional medicinal uses of A. indica in Asia, together with previous investigations from our laboratory demonstrating its antioxidant and anti‐inflammatory effects, led us to extend the current study to evaluate acetylcholinesterase inhibitory activity (AChEI). Our hypothesis focused on investigating neurological pathways such as neuroinflammation and oxidative stress associated with AD development by targeting these pharmacological activities. Thus, we aimed to evaluate, for the first time, the potential of A. indica in blocking the progression of Alzheimer's disease by simultaneously targeting three key mechanisms: senile plaques (SPs), neurofibrillary tangles (NFTs), and neuroinflammation/oxidative stress. In addition, we sought to explore other phytoactive compounds from A. indica , including acteoside, which has previously been reported to contribute to the disposition of senile plaques through a multifaceted approach (Kurisu et al. 2013; Shiao et al. 2017). Materials & Methodology Plant Extract Preparation Aeginetia indica whole plant picked up from Chandranath Hill, Chittagong, Bangladesh (22°50′59″ N 91°38′14″ E) during winter season in January 2020. Khandakar Kamrul Islam, an expert Scientific Officer of the Bangladesh National Herbarium, verified its authenticity of the plant with previously voucher specimen (DACB No‐46478). The collected plants were cleaned from the dirt properly and left in the air dry for 7 days. Then the collected plant was washed thoroughly to remove all kinds of dirt and left to air dry for 7 days before crushing into fine powder. A total of 130.53 g of fine powder was then soaked in 80% methanol for 14 days. To obtain a clear filtrate from the suspension, we used a cloth filter first and then a Whatman filter paper. The final crude methanolic extract of A. indica (AiME, 7.5%) was prepared by concentrating the clear filtrate via rotary evaporator under reduced pressure at 40°C for 6 h. A total of 9.6 g of yellowish‐brown extract was then stored at 4°C until further use. In Vitro Antioxidant Assay DPPH‐Free Radical Scavenging Assay The DPPH free radical scavenging assay is a reliable and useful in vitro method to measure antioxidative activities of phytoconstituents in plant extracts (Anu et al. 2025; Diment et al. 2025). This assay is based on the principle of a stable free radical compound, 1,1‐diphenyl‐2‐picrylhydrazyl (DPPH•), which has a deep violet color and high absorbance at 517 nm. When an antioxidant donates a hydrogen atom to DPPH•, it becomes reduced to DPPH‐H, a pale yellow, non‐radical form. Consequently, a decrease in absorbance is observed, which reflects the antioxidant capacity of the test samples. Thus, the free radical scavenging capacity of the AiME was evaluated using a modified version of this established DPPH (1,1‐diphenyl‐2‐picrylhydrazyl) radical scavenging assay (Alhakmani et al. 2013). Briefly, a 0.1 mM DPPH solution in absolute methanol was prepared fresh and kept in the dark at 4°C during the experiment. The AiME extract was serially diluted to various concentrations (10–500 μg/mL) using methanol. Subsequently, 0.3 mL aliquots of each AiME extract dilution were added to 3 mL aliquots of the DPPH solution. The reaction mixtures were incubated for 30 min in the dark to allow for reaction, followed by absorbance measurement at 517 nm. Methanol served as a blank control, whereas ascorbic acid was employed as a standard and processed identically to the plant extract. All experiments were conducted in triplicate, and the results are presented as the average value. where A 0 = absorbance value of blank sample; A t = absorbance value of the test samples. Reducing Power Capability Assay Reducing power capability is another antioxidant assay widely used to determine the overall electron‐donating ability in plant extracts (Gulcin and Alwasel 2025; Irshad et al. 2025). In this assay, the principle is the ability of test sample compounds to reduce ferric ions (Fe3+) to ferrous ions (Fe2+), a crucial parameter to assess the antioxidant activity in test samples. Therefore, the ferric reducing activity (FRA) of AiME was determined by its ability to convert ferric ions (Fe3+) to ferrous ions (Fe2+) following the method established (Anandjiwala et al. 2008). Briefly, varying concentrations (10–500 μg/mL) of the plant extract (AiME) were incubated with 2.5 mL of phosphate buffer (pH 6.6) containing 1% potassium ferricyanide (2.5 mL) at 50°C 500C for 20 min. The reaction was terminated by the addition of trichloroacetic acid (2.5 mL) and subsequent centrifugation at 3000 rpm for 10 min. The supernatant (2.5 mL) was then mixed with distilled water (2.5 mL) and freshly prepared ferric chloride solution (FeCl3, 0.1%, 0.5 mL). Absorbance of the final mixture was measured at 700 nm. Ascorbic acid served as a positive control, undergoing the same treatment as the samples. Increased absorbance values reflected greater reducing power of the extract. Each experiment was performed in triplicate, and the results were averaged for analysis. Ferric‐Reducing Antioxidant Power (FRAP) Assay The ferric reducing ability of the AiME was evaluated following a previously reported method by Benzie and Strain (1996). This modification involved the preparation of a FRAP reagent by combining 100 mL of 300 mM acetate buffer (pH 3.6), 10 mL of 10 mM TPTZ solution (in 40 mM hydrochloric acid), and 10 mL of 20 mM FeCl3.6H2O. The freshly prepared FRAP reagent was warmed to 37°C prior to use. Subsequently, 0.3 mL of various concentrations (10–500 μg/mL) of the plant extract (AiME) was added to 3 mL of the FRAP reagent in a test tube. The mixture was then incubated in darkness for 4 min, followed by absorbance measurement at 593 nm. Ascorbic acid served as a positive control, undergoing the same treatment as the plant extract samples. In Vitro Acetylcholinesterase Assay A microplate assay with minor modifications to Ellman's method (Ellman et al. 1961) was employed to assess the AiME's potential to inhibit AChE activity. Minor modifications included varying plant extract concentrations, using 405 nm instead of 412 nm, and adding DMSO as a negative control, which did not affect the evaluation of anti‐acetylcholinesterase activity. Briefly, a range of different concentrations of plant extract AiME (ranging from 0.05 to 10 mg/mL) were prepared through serial dilution and dispensed into quadruplicate wells of a microplate. After adding AiME extract to each Eppendorf tube, following the addition of extracts, each well received 50 μL of phosphate buffer (containing 8 mM K2HPO4, 2.3 mM NaH2PO4, and 0.15 M NaCl, pH 7.6) and 50 μL (0.25 U/mL) AChE enzyme from Electrophorus electricus (Sigma‐Aldrich, USA) in phosphate buffer, followed by a 20‐min incubation at 20°C. Afterwards, 25 μL of ATCI (acetylthiocholine iodide, 5.18 mg/mL) and 125 μL of 5,5′‐Dithiobis (2‐nitrobenzoic acid) (DTNB, 0.3 mg/mL) were added to each well, and the mixture was incubated for another 20 min at 37°C, leading to the formation of a yellow substance. The absorbance of this yellow substance, transferred to a 96‐well ELISA plate (A sample), was measured at 405 nm using a UV spectrophotometer. Control wells included a sample blank (A Blank) lacking AChE and the sample, and a control (A control) containing all reagents except the sample. The validity of the assay was established by comparing the control to Rivastigmine, a known AChE inhibitor. The percentage inhibition of AChE by the A. indica extract was calculated using the following equation: In Vivo Anti‐Inflammatory Study Carrageenan Treatment A total of 24 mice of both sexes were allocated into four groups of six animals each, which were bred and housed at the International Centre for Diarrheal Disease and Research in Bangladesh (ICDDRB). Figure S1, depicts paw size changes in mice during the carrageenan treatment. The animals were kept in standard laboratory conditions, which included a relative humidity of 55%–65%, ambient temperature of 25°C–28°C, and 12‐h light–dark cycles. Animals were provided with a continuous availability of food, pellets and water. Animals were divided into the following four groups: negative control, treatment group, AiME extract at 200 mg/kg, and AiME extract at 400 mg/kg. Then, a single dose of normal saline (1 mL/100 g), indomethacin 10 mg/kg, AiME 200 mg/kg, and AiME 400 mg/kg were administered orally (p.o.) to the four groups of animals, respectively. After 30 min, paw edema was induced in each mouse by injecting 0.1 mL of a 1% carrageenan solution into the plantar region of the right hind paw. All experimental procedures were conducted in compliance with the ARRIVE guidelines (Percie du Sert et al. 2020). The study protocol was approved by the institutional ethics committee under reference number (40/2020). Paw Size Measuring Paw thickness was assessed at baseline using a Vernier caliper before carrageenan injection. Subsequently, paw thickness was measured at following intervals (1, 2, 3, and 4 h) after carrageenan injection to monitor edema development. The change in paw thickness was calculated as the difference between the baseline measurement and the respective hourly measurements. LCMS/MS Analysis In the present study, a quantitative evaluation of 56 standards (53 phytochemicals and 3 deuterated internal standards) was conducted using a Shimadzu Nexera UHPLC system coupled to a tandem mass spectrometer, following the method of Yilmaz (2020). The UHPLC system consisted of an autosampler (SIL‐30AC), a column oven (CTO‐10ASvp), binary pumps (LC‐30AD), and a degasser (DGU‐20A3R). Chromatographic separation was achieved using an Agilent Poroshell 120 EC‐C18 analytical column (150 mm × 2.1 mm, 2.7 μm) maintained at 40°C. The mobile phases consisted of eluent A (water with 5 mM ammonium formate and 0.1% formic acid) and eluent B (methanol with 5 mM ammonium formate and 0.1% formic acid). The gradient profile was: 20%–100% B (0–25 min), 100% B (25–35 min), and return to 20% B (35–45 min). The flow rate and injection volume were set at 0.5 mL/min and 5 μL, respectively. Prior to LC–MS/MS analysis, extracts were diluted with methanol to a final concentration of 1 mg/mL and maintained at 15°C during analysis (Yilmaz 2020). The File S1A provides details about LC–MS/MS analysis. The LC–MS/MS chromatogram of 53 standard compounds and 3 internal standards is given in Figure S2. GCMS Analysis The tentative identification of A. indica plant constituents was achieved using a Shimadzu GC–MS QP 2020 equipped with an SH‐Rxi‐% Sil MS packed fused silica column, as explained by Settu et al. (2021). Helium served as carrier gas with a constant flow rate of 1 mL/min. The injector temperature was set to 250°C, and a 1 μL sample was injected. The temperature program employed an initial hold at 50°C for 4 min, followed by a rapid temperature increase of 8°C/min to reach a final temperature of 280°C, which was maintained for 2 min. The mass spectrometry (MS) detector operated with a transfer line temperature of 250°C, an ion source temperature of 200°C, and electron ionization (EI) mode at 70 eV. The scan parameters included a scan time of 0.30 s and a scan interval of 0.1 s, acquiring fragments within a mass range of 40–550 Da. The acquired mass spectra were then compared to those of known compounds within the GC–MS NIST library for identification purposes. In Silico Analysis Molecular Docking Study Molecular docking simulations were performed using the AutoDock Vina software, following the same protocols described in our previous study. The key residues in the active site of AChE (PDB ID: 4EY7) were identified as Tyr72, Trp86, Trp286, Ser293, Phe295, Tyr337, Phe338, and Tyr341. These residues are potentially responsible for regulating AChE physiology and activity (Jiang and Gao 2018; Kumar et al. 2024; Roca et al. 2018). A ligand library of 50 compounds was compiled using data from LC–MS/MS, GC–MS, and previously reported literature sources outlined in Table S2 (Ho et al. 2004, 2003). The reference drug rivastigmine was also included for validation. Detailed information on protein and ligand preparation, as well as grid box coordinates, is provided in File S1A. Drug‐Likeness and ADMET Properties Screening After a successful molecular docking, 12 candidate compounds derived from AiME were chosen for further analysis. This analysis evaluated their drug‐likeness properties and adherence to Lipinski's rule of five (“RO5”). The SwissAdme platform (http://www.swissadme.ch/) was utilized to compute drug‐likeness scores based on the established Lipinski rule (Jain et al. 2024). Additionally, bioavailability radars were generated for all compounds, allowing for a visual comparison of their physicochemical properties to the reference drug, rivastigmine (Daina et al. 2017). Furthermore, pkCSM (https://biosig.lab.uq.edu.au/pkcsm/) was employed to assess a comprehensive range of ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties (de Araújo et al. 2025). The inclusion of rivastigmine in both analyses served as a control, enabling the standardization of predicted values for the proposed ligands by facilitating a direct comparison with a known drug for AD. Molecular Dynamics (MD) Simulations Molecular dynamics simulations of 100 ns were conducted to examine the apoenzyme AChE in complex with the lead compounds acteoside and acacetin, following the methodology outlined in our previous study (Ahmed et al. 2024; Mazumder et al. 2022). Structural parameters, including root‐mean‐square deviation (RMSD), root‐mean‐square fluctuation (RMSF), radius of gyration (Rg), solvent‐accessible surface area (SASA), and hydrogen bond interactions, were analyzed for both complexes. Stepwise details are provided in File S1A. Statistical Analysis All data are expressed as the mean ± SEM. Statistical analyses were performed using GraphPad Prism (version 8.3.4). For the antioxidant assay, both standard and plant extract groups were analyzed by a two‐way ANOVA test. In the anti‐inflammatory assay, ANOVA was followed by Bonferroni's test. A probability level (adjusted p‐value calculated by GraphPad Prism) of 0.05 or less was considered significant; *p < 0.05, **p < 0.01, ***p < 0.001. Results In Vitro Study Results of Antioxidant Assay for AiME This study aimed to investigate the antioxidant potential of AiME and elucidate its underlying mechanism. Three assays, DPPH free radical scavenging activity, reducing power activity (RPA), and ferric‐reducing antioxidant power (FRAP) assay, were employed to assess the antioxidant properties of AiME (Figure 1a–c). Additionally, comparisons of IC50 and EC50 values between AiME and ascorbic acid (Std) are summarized in Table 1. Graphical representations for antioxidant activity of Aeginetia indica ; (a) comparison of % of inhibition results between A. indica and ascorbic acid in DPPH free radical scavenging activity, (b) result of reducing power activity (RPA), (c) ferric‐reducing antioxidant power (FRAP); AiME: methanolic extract of A. indica ; Std: ascorbic acid. TABLE 1Comparison of IC50 and EC50 values between AiME and ascorbic acid (Std) during in vitro antioxidant assay.AssaySample (N = 3)IC50 value (μg/mL)DPPH free radical scavenging activityAiME176.586 ± 5.960Ascorbic acid (Std)38.866 ± 10.059AssaySampleEC50 (μg/mL)Reducing power activity (RPA)AiME358.249 ± 16.605Ascorbic acid (Std)53.778 ± 0.624Ferric‐reducing antioxidant power (FRAP)AiME39.467 ± 9.046Ascorbic acid (Std)48.986 ± 0.512 Comparison of IC50 and EC50 values between AiME and ascorbic acid (Std) during in vitro antioxidant assay. The DPPH free radical scavenging assay revealed a similar trend of increasing activity with concentration for both AiME and standard ascorbic acid (Figure 1a). However, ascorbic acid exhibited a significantly stronger free radical scavenging ability, with an IC50 value of 38.866 ± 10.059 μg/mL compared to AiME's 176.586 ± 5.96 μg/mL (Table 1). The RPA, another indicator of antioxidant potential, was measured by the increase in absorbance at 700 nm. AiME displayed a lower reducing power (RPA) compared to ascorbic acid (Std), reaching an average maximum absorbance of 0.652 at 500 μg/mL (Figure 1b). In contrast, standard ascorbic acid exhibited an average maximum absorbance of 1.648 at 500 μg/mL. This trend mirrored the observations from the DPPH assay. The FRAP assay, another antioxidant assay, demonstrated the ferric‐reducing antioxidant power activity in AiME compared to the standard. The average maximum absorbance for AiME was 1.679 at a concentration of 500 μg/mL, whereas ascorbic acid (Std) had an average maximum value of 3.006 at the same concentration (Figure 1c). Results of In Vitro AChE Inhibition Assay for AiME Figure 2 summarizes the inhibitory activity of A. indica methanolic extract (AiME) against AChE and the corresponding IC50 values. Rivastigmine, a known AChE inhibitor, was used as the standard for comparison. Both AiME and rivastigmine exhibited concentration‐dependent inhibition (Figure 2a). Notably, AiME demonstrated a stronger inhibitory effect than the standard. The IC50 value of AiME was 1.636 ± 0.067 mg/mL, whereas rivastigmine (standard) showed an IC50 of 2.344 ± 0.151 mg/mL (Figure 2b). The lower IC50 value of AiME suggests potentially greater AChE inhibitory activity compared to rivastigmine. Comparison of percentage of inhibition results and IC50 between Aeginetia indica and rivastigmine (Std) for AChE inhibition; AiME: methanolic extract of A. indica ; Std: ascorbic acid. In Vivo Anti‐Inflammatory Study AiME demonstrated anti‐inflammatory efficacy at all provided doses, as detailed in Table 2. The study demonstrates the anti‐inflammatory effects of indomethacin (Std) and the AiME on paw edema in an experimental model. Indomethacin, a known nonsteroidal anti‐inflammatory drug, inhibited paw edema by 26.84% at the 4‐h mark, serving as a standard for comparison. In comparison with Std, our plant extract AiME at a dose of 400 mg/kg showed nearly an equivalent inhibition of 26.81% at the end of 4 h, suggesting it has similar efficacy to indomethacin at this dosage (400 mg/kg). However, at a lower dose of 200 mg/kg, AiME inhibited paw edema by 20.35% at the 4‐h mark, demonstrating a dose‐dependent response. The similar efficacy trend of edema inhibition observed in both AiME and the standard treatment is supported by a highly significant statistical difference, with p < 0.001 (***) between the two groups. TABLE 2The effects of the methanol extract of Aeginetia indica and indomethacin in carrageenan‐induced paw edema test in mice.Treatment groupPaw sizeTotal increase or decrease of paw thicknessAt 0 hAfter 1 hAfter 2 hAfter 3 hAfter 4 hNegative control2.34 ± 0.023.58 ± 0.053.57 ± 0.113.43 ± 0.063.39 ± 0.0744.87% ↑Standard indomethacin2.38 ± 0.062.99 ± 0.09***2.73 ± 0.10***2.68 ± 0.05***2.48 ± 0.06***26.84% ↓ A. indica 200 mg/kg2.43 ± 0.033.1 ± 0.14***2.95 ± 0.10***2.76 ± 0.08***2.70 ± 0.06***20.35% ↓ A. indica 400 mg/kg2.37 ± 0.022.83 ± 0.08***2.7 ± 0.10***2.63 ± 0.09***2.48 ± 0.07***26.81% ↓ Note: (↑) indicate percentage increase of paw edema size after 4 h compared to 0 h. (↓) indicate percentage decrease of paw edema size after 4 h compared to negative control group. All values are given in mean ± SEM. N = 6. Significantly different from negative control at *p < 0.05, **p < 0.01, and ***p < 0.001. The effects of the methanol extract of Aeginetia indica and indomethacin in carrageenan‐induced paw edema test in mice. Note: (↑) indicate percentage increase of paw edema size after 4 h compared to 0 h. (↓) indicate percentage decrease of paw edema size after 4 h compared to negative control group. All values are given in mean ± SEM. N = 6. Significantly different from negative control at *p < 0.05, **p < 0.01, and ***p < 0.001. Phytochemical Study Results From LCMS Analysis The polyphenolic composition of the AiME was analyzed by LC–MS/MS analysis, and the findings are presented in Table 3. This analysis identified 16 polyphenolic compounds in the AiME extract through comparison with standards. The corresponding chromatogram for AiME is presented in Figure 3, whereas the LC–MS/MS chromatogram of the standard compounds is provided in Figure S2. The overall analytical method validation parameters employed by this study are also summarized in Table S1. Quantitative analysis revealed that the four most abundant polyphenols in AiME were acacetin (2.972 mg/g), fumaric acid (2.544 mg/g), vanilic acid (1.926 mg/g), and luteolin (1.460 mg/g). Other major identified compounds included protocatechuic acid (1.449 mg/g), apigenin (0.895 mg/g), and caffeic acid (0.652 mg/g). Protocatechuic aldehyde, quinic acid, vanillin, syringic acid, and p‐coumaric acid were all found in lower amounts of 0.379 mg/100 g, 0.332, 0.294, and 0.122 mg/g, respectively. The phenolics with the lowest abundances were naringenin (0.081 mg/g), hesperetin (0.037 mg/g), hesperidin (0.024 mg/g), and cosmosin (0.023 mg/g). Compounds such as acacetin, luteolin, caffeic acid, and vanillic acid are known to inhibit lipid oxidation and oxidative degradation in food matrices, whereas flavonoids like apigenin and naringenin have been associated with functional food development owing to their potential health‐promoting effects (Parveen et al. 2025). The abundance of diverse polyphenolic compounds in AiME suggests strong natural antioxidants, anti‐inflammatory potential, which may help reduce oxidative stress in the body when consumed as a dietary supplement (Sun et al. 2024). Moreover, its enriched polyphenolic profile highlights the significance of this herbal plant for the food and beverage industries, particularly for its potential use as an anti‐browning agent (Ho 1992). Collectively, the diverse polyphenolic profile of AiME supports its potential application as a natural functional ingredient or nutraceutical additive in food systems (Martínez‐Zamora et al. 2023). TABLE 3Identification and quantification of phenolic compounds of Aeginetia indica by LC–MS/MS.AnalytesAiME (mg analyte/g extract)R.T.MI (m/z)FI (m/z)Quinic acid0.3233.0190.893.0Fumaric acid2.5443.9115.240.9Aconitic acidN.D.4.0172.8129.0Gallic acidN.D.4.4168.879.0EpigallocatechinN.D.6.7304.8219.0Protocatechuic acid1.4496.8152.8108.0CatechinN.D.7.4288.8203.1Gentisic acidN.D.8.3152.8109.0Chlorogenic acidN.D.8.4353.085.0Protocatechuic aldehyde0.3798.5137.292.0Tannic acidN.D.9.2182.878.0Epigallocatechin gallateN.D.9.4457.0305.11,5‐dicaffeoylquinic acidN.D.9.8515.0191.04‐OH benzoic acidN.D.10.5137.265.0EpicatechinN.D.11.6289.0203.0Vanillic acid1.92611.8166.8108.0Caffeic acid0.65212.1179.0134.0Syringic acid0.29412.6196.8166.9Vanillin0.33213.9153.1125.0Syringic aldehydeN.D.14.6181.0151.1DaidzinN.D.15.2417.1199.0Epicatechin gallateN.D.15.5441.0289.0PiceidN.D.17.2391.0135/106.9 p‐coumaric acidN.D.17.8163.093.0Ferulic acid‐D3‐IS*N.A.18.8196.2152.1Ferulic acidN.D.18.8192.8149.0Sinapic acidN.D.18.9222.8193.0CoumarinN.D.20.9146.9103.1Salicylic acidN.D.21.8137.265.0CynarosideN.D.23.7447.0284.0MiquelianinN.D.24.1477.0150.9Rutin‐D3‐IS*N.A.25.5612.2304.1p‐Coumaric acid0.12217.8163.093.0Hesperidin0.02425.8611.2449.0 o‐Coumaric acidN.D.26.1162.893.0GenistinN.D.26.3431.0239.0Rosmarinic acidN.D.26.6359.0197.0Ellagic acidN.D.27.6301.0284.0Cosmosin0.02328.2431.0269.0QuercitrinN.D.29.8447.0301.0AstragalinN.D.30.4447.0255.0NicotiflorinN.D.30.6592.9255.0/284.0FisetinN.D.30.6285.0163.0DaidzeinN.D.34.0253.0223.0Quercetin‐D3‐IS*N.D.35.6304.0275.9QuercetinN.D.35.7301.0136.0/286.0Naringenin0.08135.9270.9119.0Hesperetin0.03736.7301.0136.0/286.0Luteolin1.46036.7284.8151.0/175.0GenisteinN.D.36.9269.0135.0KaempferolN.D.37.9285.0239.0Apigenin0.89538.2268.8151.0/149.0AmentoflavoneN.D.39.7537.0417.0ChrysinN.D.40.5252.8145.0/119.0Acacetin2.97240.7283.0239.0Abbreviations: FI (m/z), fragment ions; MI (m/z), molecular ions of the standard analytes (m/z ratio); N.D., not detected; NA, not applicable; R.T., retention time. Identification and quantification of phenolic compounds of Aeginetia indica by LC–MS/MS. Abbreviations: FI (m/z), fragment ions; MI (m/z), molecular ions of the standard analytes (m/z ratio); N.D., not detected; NA, not applicable; R.T., retention time. LC–MS/MS chromatogram of Aginetia indica whole plant extract. Results From GCMS Analysis GC–MS analysis was employed to tentatively identify potential phytochemical compounds in the AiME. The characteristic GC–MS chromatogram of AiME is presented in Figure 4. A total of 23 compounds were identified in the AiME and are listed in Table 4. This table includes the retention time, molecular weight, molecular formula, percentage area, and other relevant information for each compound identified by GC–MS analysis. GCMS chromatogram for Aginetia indica whole plant extract. TABLE 4List of identified polyphenolic compounds from the methanolic extract of Aeginetia indica via GCMS analysis.Sl. no.Compound ( A. indica )R. time m/z MW (g/mol)Molecular formulaArea12H‐1,4‐Benzodiazepin‐2‐one, 7‐chloro‐1,3‐dih5.83573310.48C19H34O3 64,1192Benzeneacetic acid, 3‐nitro—7.72173154.20C9H14O2 64,1193Galacto‐heptulose8.04667294.50C19H34O40,4344Phloroglucinol9.10374340.60C22H44O2 135,32051,2‐Benzenedicarboxylic acid, butyl octyl ester9.85474214.34C13H26O2 345,3156Tetrahydro‐4H‐pyran‐4‐ol10.56674298.50C19H38O2 345,3157Gamma‐Guanidinobutyric acid10.92559281.50C18H35NO350,1718Methoprene12.51973258.43C13H26O3Si64,1199Phthalic acid, butyl ester, ester with butyl glycol12.79674284.50C18H36O2 135,32010Methyl tetradecanoate13.46359309.53C20 H39NO350,17111Bicyclo[3.1.0]hexane‐2‐undecanoic acid, methyl ester14.09173320.50C21H36O2 47,4411212,15‐Octadecadienoic acid, methyl ester15.18674284.50C18H36O2 345,31513Linoelaidic acid15.18673310.48C17H32O4Si3 47,4411410‐Undecyn‐1‐ol15.3544145.16C5H11N3O2 20,48115Docosanoic acid, methyl ester15.49473266.50C18H34O47,44116Trimethylsilyl 3‐methyl‐4‐ [(trimethylsilyl)oxy]16.93274242.40C15H30O2 345,31517Dodecanoic acid, 2,3‐bis (acetyloxy)propyl ester18.49767280.44C18H32O40,434182,5‐Dihydroxybenzoic acid, 3TMS derivative19.46674270.45C17H34O345,31519Octadecanoic acid, 2,3‐dihydroxypropyl ester19.9273310.48C18H37NO3Si3 47,441201,2‐Ethanediamine, N‐(2‐aminoethyl)—20.68344198.30C12H22O2 807821Cyclopentadecanone, oxime23.39473294.47C19H34O47,441229‐Octadecenamide, (Z)—24.53644184.28C11H20O2 8078237,7,9,9,11,11‐Hexamethyl‐3,6,8,10,12,15‐hex29.6173322.50C21H38O2 47,441 List of identified polyphenolic compounds from the methanolic extract of Aeginetia indica via GCMS analysis. Molecular Docking Analysis A total of 45 compounds, including the reference standard rivastigmine, were docked against AChE to evaluate their binding affinities. Table 5 summarizes the results in ascending order. Notably, 19 AiME‐derived compounds displayed superior binding affinities (−10.9 to −8.2 kcal/mol) compared to rivastigmine (−8.1 kcal/mol). Hesperidin emerged as the most promising candidate with the strongest binding affinity (−10.9 kcal/mol). Several other compounds, including aegineoside, acacetin, and luteolin, also demonstrated promising potential with affinities exceeding −10.0 kcal/mol. Furthermore, acteoside, ficusal, cosmosin, aeginetic acid, and aeginetolide exhibited affinities (−9.6 to −8.5 kcal/mol) surpassing rivastigmine. TABLE 5Docking score of identified phytochemical compounds and standard drug (rivastigmine) in the binding site of acetylcholinesterase (4ey7) computed via Autodoc Vina Software.Sl. no.LigandCIDBinding affinity (kcal/mol)1Hesperidin10,621−10.92Aegineoside132,353,271−10.73Acacetin5,280,442−10.44Hesperetin72,281−10.45Luteolin5,280,445−10.46Naringenin439,246−10.37Stigmaserol5,280,794−10.28Apigenin5,280,443−10.29Balanophonin23,252,258−10.110Beta‐sitosterol222,284−10.011Acteoside5,281,800−9.612Ficusal10,496,641−9.013Cosmosin6,336,505−8.714Aeginetic acid15,693,867−8.7151,2‐Benzenedicarboxylic‐acid‐butyl‐octyl‐ester66,540−8.616Bicyclo[3.1.0]hexane‐2‐undecanoic acid, methyl ester557,192−8.517Aeginetolide15,948,056−8.518Cyclopentadecanone oxime551,985−8.419Methoprene5,366,546−8.220Rivastigmine77,991−8.1219‐Octadecenamide, E5,362,793−7.722Benzeneacetic acid, 3‐nitro—15,876−7.723Linoelaidic acid5,282,457−7.724Caffeic acid689,043−7.725Octadecanoic acid, 2,3‐dihydroxypropyl ester24,699−7.626p‐Coumaric acid637,542−7.62712,15‐Octadecadienoic acid, methyl ester5,365,571−7.428Methyl tetradecanoate31,284−7.329β‐sitosteryl glucoside5,742,590−7.130Vanillic acid8468−6.8312‐Dodecenoic acid5,282,729−6.732Quinic acid6508−6.633Protocatechuic acid72−6.634Syringic acid10,742−6.63510‐Undecyn‐1‐ol76,015−6.436Protocatechuic aldehyde8768−6.237Vanillin1183−6.238Galacto‐heptulose102,926−5.739Gamma‐Guanidinobutyric acid500−5.640Phloroglucitol230,351−5.241β‐sitosteryl glucoside5,742,590−5.042Trans‐coniferaldehyde5,280,536−4.843Fumaric acid444,972−4.644Tetrahydro‐4H‐pyran‐4‐ol74,956−4.4451,2‐Ethanediamine‐N‐(2‐aminoethyl)—8111−4.0 Docking score of identified phytochemical compounds and standard drug (rivastigmine) in the binding site of acetylcholinesterase (4ey7) computed via Autodoc Vina Software. Based on these findings, 12 compounds were selected as potential “hit” candidates for AChE inhibition, considering their abundance in AiME and promising docking scores, and previous histories of association with acetylcholinesterase activity. The three best “lead” compounds (acteoside, acacetin, and luteolin) were further analyzed for their bonding interactions with AChE, presented in Table 6. Similar analyses for the remaining 9 hit compounds are provided in Table S3. Notably, the three lead compounds displayed equal or more hydrogen bonds with AChE compared to rivastigmine. To comprehensively understand the protein‐ligand interactions, 2d representations for all hit compounds are provided in Figure S3. Additionally, 3d structural representations in Figure 5 and Figure S4 visually depict these interactions for all selected lead candidates. TABLE 6Bond analysis among the three lead phytoconstituents and rivastigmine (standard) with acetylcholinesterase enzyme (AchE). Bond analysis among the three lead phytoconstituents and rivastigmine (standard) with acetylcholinesterase enzyme (AchE). Possible 3D interactions of (A) acteoside, (B) acacetin, (C) luteolin, (D) rivastigmine with acetylcholinesterase (AChE) (PDB ID: 4EY7) (pose predicted by PyMoL). Drug Likeliness, ADMET, Bioavailability Radar Analysis Twelve hit compounds were assessed for drug‐likeness and ADMET properties (summarized in Tables 7 and 8). All compounds except acteoside, hesperidin, and aeginetolide adhered to Lipinski's Rule (Jain et al. 2024). Additionally, all compounds, except them, displayed high value for the GI absorption. Despite acteoside's limited water solubility (MLOGP < 5), it was retained due to potential mitigation strategies such as chitosan‐coated liposomes described by Xiao et al. (2022). Interestingly, both acacetin and luteolin, among the selected three best lead compounds, exhibited a TPSA value within the optimal range of 20–130 Å2, suggesting good potential for crossing biological barriers, such as absorption and brain access, which is important for AD drugs (Gandla et al. 2023). TABLE 7Evaluation of drug likeliness properties of nine lead compounds and rivastigmine by examining Lipinski rules violations.CompoundMolecular formulaMW (g/mol)NHANHDTSPAGI absorptionLog Po/w (MLOGP)Lead likenessLipinski violationsActeosideC29H36O15 624.59159245.29Low−2.37No: 2 violations3 violationsHesperidinC28H34O15 610.56158234.29Low−3.04No: 1 violation3 violationsAcacetinC16H12O5 284.265279.90High0.77Yes0 violationHesperetinC16H14O6 302.286396.22High0.41Yes0 violationLuteolinC15H10O6 286.2464111.13High−0.03Yes0 violationNaringeninC15H12O5 272.255386.99High0.71Yes0 violationAegineosideC26H30O12 534.51126184.60Low−1.15No: 2 violations3 violationsAeginetic acidC15H24O4 268.354377.76High1.62Yes0 violationAeginetolideC11H18O3 198.263146.53High1.60No: 1 violation0 violationApigeninC15H10O5 270.245390.90High0.52Yes0 violationBalanophoninC20H20O6 356.376285.22High1.01No: 1 violation0 violationFicusalC18H18O6 330.336285.22High0.63Yes0 violationRivastigmineC14H22N2O2 250.346332.78High2.34Yes0 violation Evaluation of drug likeliness properties of nine lead compounds and rivastigmine by examining Lipinski rules violations. TABLE 8ADMET properties analysis of the best 10 compounds with rivastigmine (standard).ParameterActeosideSelected phytoconstituentsSTDReference valueHesperidinAcacetinHesperetinLuteolinNaringeninAegineosideAeginetic acidAeginetolideApigeninBalanophoninFicusalRivastigmineAbsorptionWater solubility (log mol/L)−2.90−3.01−3.28−3.04−3.09−3.22−3.40−1.64−2.04−3.32−4.24−3.72−2.35—Caco2 permeability0.090.501.130.290.091.02−0.630.881.231.001.271.261.57High: > 0.90Intestinal absorption32.1131.4894.3170.2781.1391.3120.8294.1895.2193.2596.0495.8388.46Poor: < 30%Skin permeability−2.73−2.73−2.73−2.73−2.73−2.74−2.73−2.73−3.58−2.73−2.75−2.82−2.88Low: > −2.5P‐glycoprotein substrateYesYesYesYesYesYesYesNoNoYesYesYesNoYes/NoDistributionVdss (human) (log L/kg)2.250.990.340.741.15−0.01−0.84−0.830.200.82−0.21−0.100.63 Low: < −0.15 High: > 0.45 Fraction unbound (human) (Fu)0.260.100.080.110.160.060.1620.470.610.140.0030.060.54—BBB permeability−1.86−1.71−0.19−0.71−0.90−0.570.162−0.640.62−0.73−0.19−0.370.51 Good: > 0.3 Poor: < −1 CNS permeability−4.60−4.80−2.15−2.97−2.25−2.21−4.14−2.950.62−2.06−3.02−3.16−2.25 Permeable: > −2 Not permeable: < −3 MetabolismCYP2D6 substrateNoNoNoNoNoNoNoNoNoNoNoNoNoYes/NoCYP3A4 substrateNoNoYesNoNoNoNoNoNoNoYesYesNoYes/NoCYP1A2 inhibitorNoNoYesNoYesYesNoNoNoYesNoNoNoYes/NoCYP2C19 inhibitorNoNoYesNoNoNoNoNoNoYesYesYesNoYes/NoCYP2C9 inhibitorNoNoYesNoYesNoNoNoNoNoYesNoNoYes/NoCYP2D6 inhibitorNoNoNoNoNoNoNoNoNoNoNoNoYesYes/NoCYP3A4 inhibitorNoNoYesNoNoNoNoNoNoNoYesYesNoYes/NoExcretionTotal clearance (log mL/min/kg)0.470.210.660.040.490.06−0.071.2810.560.070.090.56Higher is betterRenal OCT2 substrateNoNoNoNoNoNoNoNoNoNoNoNoNoYes/NoToxicityAMES toxicityNoNoNoNoNoNoNoNoNoNoNoNoNoYes/NohERG I inhibitorNoNoNoNoNoNoNoNoNoNoNoNoNoYes/NoMax. tolerated dose (human) (log mg/kg/day)0.440.520.090.250.49−0.170.400.320.680.33−0.220.010.38—Oral rat acute toxicity (LD50) (mol/kg)2.522.502.222.042.451.792.801.862.042.452.172.133.40—HepatotoxicityNoNoNoNoNoNoNoNoNoNoNoNoNoYes/No ADMET properties analysis of the best 10 compounds with rivastigmine (standard). Low: < −0.15 High: > 0.45 Good: > 0.3 Poor: < −1 Permeable: > −2 Not permeable: < −3 Bioavailability radar results are summarized in Figure S5. Overall, the results indicate that our best leads, being physiochemically polar in nature, exhibit poor oral bioavailability compared to the standard rivastigmine. Therefore, these leads may require specialized formulation strategies such as prodrug design by masking polar groups with lipophilic moieties or incorporation into lipid‐based nanocarrier systems (Xiao et al. 2022). Then, ADMET prediction indicated promising pharmacokinetic profiles for all compounds, comparable to rivastigmine. Notably, acteoside showed a more favorable distribution profile than rivastigmine (Vdss = 2.255 log L/kg vs. 0.625 log L/kg, Fu = 0.26 vs. 0.54). Also, acteoside exhibited a more favorable distribution profile than rivastigmine (Vdss = 2.255 log L/kg vs. 0.625 log L/kg, Fu = 0.26 vs. 0.54). Despite the fact that rivastigmine had the highest BBB permeability score (0.51), both acacetin and luteolin also showed potential as CNS drug candidates with scores of −2.15 and −2.25, respectively, which were like rivastigmine's score of −2.25. Metabolic evaluation yielded varied results. Acteoside displayed no cytochrome P450 inhibition, whereas acacetin inhibited all isoforms except CYP2D6, and luteolin inhibited CYP1A2 and CYP2C9. Regarding excretion, the three best leads (acteoside, acacetin, and luteolin) showed comparable or higher total clearance (log mL/min/kg) compared to rivastigmine. Additionally, all compounds were negative for renal OCT2 substrate, a crucial parameter for oral formulations. Toxicity analysis revealed a non‐hepatotoxic, non‐mutagenic (AMES test), and negative hERG I inhibitor profile for all hits, like rivastigmine. However, acteoside and luteolin exhibited the highest predicted human maximum tolerated dose (0.44 and 0.49 log mg/kg/day) compared to rivastigmine (0.382 log mg/kg/day). The oral rat acute toxicity (LD50) for these three best leads was also comparable to rivastigmine. Overall, based on favorable ADMET profiles, potential AChE inhibition, and additional factors (acteoside's past association with AD and abundance of acacetin/luteolin in the extract), acteoside, acacetin, and luteolin were identified as the most promising lead compounds for further development as AChE inhibitors for Alzheimer's disease. In conclusion, Figure 6 schematically depicts the entire process of prime lead selection, encompassing the initial identification of compounds, followed by hit generation, and culminating in the evaluation of drug‐likeness and ADMET properties. Overview of the screening process for the generation of three prime leads acteoside and acacetin. Molecular Dynamics Simulations This study employed a 100 ns MD simulation to investigate the binding stability of complexes formed between lead compounds (acteoside and acacetin) and AChE. Root Mean Square Deviation (RMSD) analysis served as the primary metric to assess complex stability. Lower RMSD values correspond to a more stable complex with minimal fluctuations, whereas higher values indicate potential structural instability (Bhattacharya et al. 2025). The RMSD analysis indicated that the alpha carbon of apo AChE remained within a range of 0.1–0.35 nm throughout the simulation (Figure 7a). Notably, the acteoside‐AChE complex demonstrated remarkable stability, with consistently lower RMSD values between 0.1 and 0.3 nm. Initially, the RMSD values for the acacetin‐AChE complex ranged from 0.1 to 0.4 nm. However, as the simulation progressed, this complex also exhibited enhanced stability, with RMSD values decreasing to a range of 0.2–0.3 nm. Furthermore, RMSF analysis was conducted to evaluate the flexibility and stability of the complexes by examining atomic deviations within residues. Lower RMSF values indicate greater stability and less flexibility (Bhattacharya et al. 2025). The RMSF profile (Figure 7b) showed minimal fluctuations for both acteoside and acacetin, suggesting well‐defined and stable structures for the complexes. Molecular dynamics features of acteoside and acacetin for acetylcholinesterase during 100 ns of simulation (a) RMSD (b) RMSF (c) Rg (d) SASA. Color indicators: black (apo‐enzyme), red (acteoside), and green (acacetin). The radius of gyration (Rg) was used as another metric to assess the compactness and rigidity of the protein‐ligand complexes. Lower Rg values signify a more compact and rigid complex structure due to favorable protein‐ligand interactions (Rehman et al. 2022). The Rg analysis for both the acteoside‐AChE and acacetin‐AChE complexes (Figure 7c) supported this observation. The Rg values were relatively lower and constant, ranging between 2.28 and 2.38 nm, compared to the alpha carbon of apo AChE, which ranged between 2.28 and 2.40 nm. This suggests that the lead‐induced complexes adopted more compact and rigid conformations. Solvent accessible surface area (SASA) analysis provided insights into potential conformational changes experienced by the protein and ligand during binding. An increase in SASA indicates possible alterations in protein or ligand orientation, whereas a decrease suggests that the ligand induces a more compact conformation for the protein upon binding. The SASA profile for both leads showed a decreasing trend compared to the alpha carbon of apo‐AChE, suggesting potential conformational changes (Figure 7d). Finally, the number of intermolecular hydrogen bonds was monitored to assess the binding affinity between the complexes formed by acteoside and acacetin with AChE. The acteoside complex initially formed 4–12 hydrogen bonds, followed by a gradual stabilization at 2–8 bonds, indicating a favorable interaction (Figure 8a). The acacetin‐AChE complex also formed 0–2 hydrogen bonds throughout the simulation (Figure 8b), indicating stable interactions with the target apo AChE. Number of hydrogen bond interactions between (a) acetylcholinesterase and acteoside, (b) acetylcholinesterase and acacetin during 100 ns simulation. Discussion Alzheimer's disease (AD) remains a significant public health burden, characterized by progressive decline in memory and cognitive function. A hallmark of AD is a deficiency in acetylcholine (ACh), a crucial neurotransmitter for cognition. AD pathology involves the buildup of neurofibrillary tangles (NFTs) and senile plaques (SPs) in the brain (Kumar et al. 2015; Silvestrelli et al. 2006), leading to chronic inflammation and increased activity of the enzyme AChE in affected areas. This ultimately results in ACh deficiency (Dos Santos Picanco et al. 2018). Another key mechanism implicated in AD development is sustained oxidative stress and neuroinflammation (Agostinho et al. 2010; Verdile et al. 2015). Its activation worsens AD by promoting amyloid plaque formation and tau hyperphosphorylation (NFT development) (Agostinho et al. 2010; Kinney et al. 2018). Existing research demonstrates the effectiveness of phenolic compounds in hindering AChE activity, which translates to a prolonged presence of ACh in the synaptic cleft, potentially improving cognitive function in AD (Taslimi et al. 2017; Zaidi et al. 2019). These compounds achieve AChE inhibition through various mechanisms including competitive and non‐competitive inhibition. Phenolic compounds from medicinal plants have garnered growing interest for their ability to inhibit AChE activity (Shiao et al. 2017). Therefore, our study aimed to investigate the potential of A. indica derived phenolic compounds to inhibit AChE activity and their possible mechanisms in AD management. To elucidate the possible mechanisms of A. indica derived phenolic compounds for AD management, three lead phenolic compounds (acteoside, acacetin, and luteolin) were selected from AiME based on a combined approach considering molecular docking scores, drug‐likeness, ADMET parameters, and their reported associations with amyloid plaque reduction (Nisa et al. 2023; Park et al. 2018; Shiao et al. 2017). Our selection process identified acteoside as one of the most promising leads. Notably, previous research has demonstrated its ability to inhibit β‐amyloid peptide and the NF‐kB pathway (He et al. 2011; Li et al. 2021; Shiao et al. 2017; Xiao et al. 2022), which aligns with our hypothesized mechanism for A. indica's impact on AD. Furthermore, LCMS/MS analysis confirmed that acacetin and luteolin, the other two selected leads, were abundantly present in the AiME. Molecular docking simulations provided further support for these selections. The study revealed strong hydrogen bond formation between the selected lead compounds (acteoside, acacetin, and luteolin) and the catalytic site of AChE. The findings suggest their potential to competitively inhibit AChE, potentially altering AD progression. Beyond AChE inhibition, our study also revealed significant anti‐inflammatory and antioxidant properties of A. indica . These properties could offer additional benefits by mitigating a third core pathophysiological aspect of AD progression. Furthermore, MD simulations demonstrated stable and rigid interactions between the two most promising leads (acteoside and acacetin) and AChE, further strengthening their potential as AChE inhibitors. To show the possible pathways through which A. indica may target oxidative stress, neuroinflammation, and AChE activity in AD, a mechanistic pathway is provided in Figure 9. The possible mechanistic pathway of Aeginetia indica in AD management. In a nutshell, this study, together with previously reported pharmacological activities of A. indica (including anti‐inflammatory, antipyretic, analgesic, hepatoprotective, and anti‐diabetic effects) (Bhuiyan et al. 2025; Hong et al. 2015; Lin et al. 2018; Parnell 2001; Reza et al. 2021, 2020), highlights its potential as a promising candidate for nutraceutical development. Positioning A. indica within the framework of food and nutritional sciences opens new avenues for formulating plant‐based supplements that can serve as natural alternatives to conventional therapeutics. Such nutraceuticals may provide multifunctional health benefits for managing everyday health challenges while minimizing the adverse side effects often associated with synthetic drugs. This perspective underscores the importance of integrating medicinal plants into functional food research, thereby bridging traditional pharmacology with modern nutritional science. Conclusion The present study investigated the antioxidant, anti‐inflammatory, and acetylcholinesterase inhibitory properties of phenolic phytoconstituents from AiME. A multifaceted approach, including in vitro antioxidant and acetylcholinesterase assays, validated the efficacy of AiME as both an antioxidant and acetylcholinesterase inhibitor (AChEI). In vivo anti‐inflammatory tests showed significant activity, whereas molecular docking studies supported the effective binding of acteoside, acacetin, and luteolin to the AChE catalytic site, suggesting a mechanistic basis for the observed AChE inhibition. Molecular dynamics simulations demonstrated favorable rigidity and stability of acteoside and acacetin with AChE during 100 ns simulations. Although these findings highlight AiME as a promising natural source of bioactive compounds that may influence multiple neurodegenerative pathways involved in AD pathogenesis. Further AD relevant investigations, including evaluation of amyloid and tau‐related markers as well as extensive clinical studies, are needed to establish the effectiveness of AiME as a natural therapeutic candidate for AD. Furthermore, the diverse pharmacological activities of A. indica present this herb as a promising candidate for nutraceutical formulations or dietary supplements that may provide multifunctional health benefits in managing everyday health challenges. Author Contributions Mustafa Abdullah Yilmaz: data curation, software, validation, formal analysis. Md. Sharif Reza: conceptualization, methodology, investigation, writing – original draft. Nuraniye Eruygur: conceptualization, supervision, writing – review and editing. Syed Mumtahin Mannan Siam: formal analysis, visualization. Marjanur Rahman Bhuiyan: conceptualization, investigation, methodology, writing – original draft. Abbas Tarhan: validation, formal analysis. Sadikur Rahman Shuvo: methodology, software, formal analysis, visualization. A. F. M. Shahid Ud Daula: conceptualization, writing – original draft, writing – review and editing, investigation, supervision, resources. Md. Nazmul Islam Durjoy: conceptualization, methodology, investigation, writing – original draft. Md. Shadman Sakib: formal analysis, visualization. Oguz Cakir: data curation, validation. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Mice paw size. (a) Non‐inflamed paw; (b) inflamed paw after carrageenan injection. Figure S2: LC–MS/MS chromatogram of standard compounds. Figure S3: 2d conformations of acetylcholinesterase enzyme (AChE) with five potential ligands: (A) acteoside, (B) acacetin, (C) balanophonin, (D) hesperetin, (E) luteolin, (F) naringenin, (G) ficusal, and (H) rivastigmine (standard) produced by Ligplot+. Figure S4: Possible 3d interactions of (A) balanophonin, (B) hesperetin, (C) naringenin, (D) ficusal with acetylcholinesterase (AchE) (pdb id: 4ey7) (pose predicted by PyMoL). Figure S5: Bioavailability radar of lead compounds of Aeginetia indica with standard rivastigmine as following:(A) acteoside, (B) acacetin, (C) balanophonin, (D) hesperetin, (E) luteolin, (F) naringenin, (G) ficusal, and (H) rivastigmine. Table S1: Analytical method validation parameters that belong to the LC–MS/MS method. Table S2: Lists of previously identified components from Aeginetia indica for their different bioactivities. Table S3: Bond analysis of the selected phytoconstituents and rivastigmine (standard) with acetylcholinesterase enzyme (AChE). Acknowledgments The authors are grateful to the Research Cell, Noakhali Science and Technology University, for partial financial assistance in conducting this research. Declaration of generative AI and AI‐assisted technologies in the writing process: During the preparation of this work, the author(s) used OpenAI's ChatGPT (Mar 14 version) to improve the readability and language of the manuscript. After using this tool/service, the author(s) reviewed and edited the content as needed and took full responsibility for the content of the publication. Contributor Information Nuraniye Eruygur, Email: nuraniye.eruygur@selcuk.edu.tr. A. F. M. Shahid Ud Daula, Email: afm.daula@just.edu.bd. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1: Mice paw size. (a) Non‐inflamed paw; (b) inflamed paw after carrageenan injection. Figure S2: LC–MS/MS chromatogram of standard compounds. Figure S3: 2d conformations of acetylcholinesterase enzyme (AChE) with five potential ligands: (A) acteoside, (B) acacetin, (C) balanophonin, (D) hesperetin, (E) luteolin, (F) naringenin, (G) ficusal, and (H) rivastigmine (standard) produced by Ligplot+. Figure S4: Possible 3d interactions of (A) balanophonin, (B) hesperetin, (C) naringenin, (D) ficusal with acetylcholinesterase (AchE) (pdb id: 4ey7) (pose predicted by PyMoL). Figure S5: Bioavailability radar of lead compounds of Aeginetia indica with standard rivastigmine as following:(A) acteoside, (B) acacetin, (C) balanophonin, (D) hesperetin, (E) luteolin, (F) naringenin, (G) ficusal, and (H) rivastigmine. Table S1: Analytical method validation parameters that belong to the LC–MS/MS method. Table S2: Lists of previously identified components from Aeginetia indica for their different bioactivities. Table S3: Bond analysis of the selected phytoconstituents and rivastigmine (standard) with acetylcholinesterase enzyme (AChE). Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.